International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Effect of Abstinence on Depression, Anxiety, and Quality of Life in Chronic Methamphetamine Users in a Therapeutic Community

Maryam Bagheri 1 , Azarakhsh Mokri 2 , Aliakbar Khosravi 1 and Kourosh Kabir 3 , *
Authors Information
1 Central Tehran Branch, Islamic Azad University, Tehran, IR Iran
2 Clinical Department, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, IR Iran
3 Community Medicine Department, School of Medicine, Alborz University of Medical Sciences, Karaj, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: September 01, 2015, 4 (3); e23903
  • Published Online: September 1, 2015
  • Article Type: Research Article
  • Received: September 26, 2014
  • Revised: December 10, 2014
  • Accepted: January 4, 2015
  • DOI: 10.5812/ijhrba.23903

To Cite: Bagheri M, Mokri A, Khosravi A, Kabir K. Effect of Abstinence on Depression, Anxiety, and Quality of Life in Chronic Methamphetamine Users in a Therapeutic Community, Int J High Risk Behav Addict. 2015 ;4(3):e23903. doi: 10.5812/ijhrba.23903.

Abstract
Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012; 379(9810): 55-70[DOI][PubMed]
  • 2. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006; 31(5): 301-13[PubMed]
  • 3. Singleton J, Degenhardt L, Hall W, Zabransky T. Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend. 2009; 105(1-2): 1-8[DOI][PubMed]
  • 4. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904): 1575-86[DOI][PubMed]
  • 5. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904): 1564-74[DOI][PubMed]
  • 6. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006; 26(8): 1148-56[DOI][PubMed]
  • 7. Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007; 76(8): 1169-74[PubMed]
  • 8. Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009; 17(4): 291-4[DOI][PubMed]
  • 9. Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010; 105(6): 991-1002[DOI][PubMed]
  • 10. Lake CR, Quirk RS. CNS stimulants and the look-alike drugs. Psychiatr Clin North Am. 1984; 7(4): 689-701[PubMed]
  • 11. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007; 47: 681-98[DOI][PubMed]
  • 12. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010; 48(7): 675-94[DOI][PubMed]
  • 13. Suzuki O, Hattori H, Asano M, Oya M, Katsumata Y. Inhibition of monoamine oxidase by d-methamphetamine. Biochem Pharmacol. 1980; 29(14): 2071-3[PubMed]
  • 14. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45: 54-63[DOI][PubMed]
  • 15. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am. 2013; 36(2): 261-75[DOI][PubMed]
  • 16. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, et al. Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict. 2010; 19(5): 385-90[DOI][PubMed]
  • 17. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003; 6(4): 347-52[DOI][PubMed]
  • 18. Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010; 105(10): 1809-18[DOI][PubMed]
  • 19. Iudicello JE, Woods SP, Vigil O, Scott JC, Cherner M, Heaton RK, et al. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J Clin Exp Neuropsychol. 2010; 32(7): 704-18[DOI][PubMed]
  • 20. Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005; 2(4): 194-9[PubMed]
  • 21. Gettig JP, Grady SE, Nowosadzka I. Methamphetamine: putting the brakes on speed. J Sch Nurs. 2006; 22(2): 66-73[PubMed]
  • 22. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974; 7: 151-69[PubMed]
  • 23. Beck AT, Rial WY, Rickels K. Short form of depression inventory: cross-validation. Psychol Rep. 1974; 34(3): 1184-6[PubMed]
  • 24. Furlanetto LM, Mendlowicz MV, Romildo Bueno J. The validity of the Beck Depression Inventory-Short Form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients. J Affect Disord. 2005; 86(1): 87-91[DOI][PubMed]
  • 25. Scogin F, Beutler L, Corbishley A, Hamblin D. Reliability and validity of the short form Beck Depression Inventory with older adults. J Clin Psychol. 1988; 44(6): 853-7[PubMed]
  • 26. Cattell RB, Scheier IH. Handbook for the IPAT Anxiety Scale Questionnaire: Self Analysis Form. 1963;
  • 27. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992; 305(6846): 160-4[PubMed]
  • 28. Hojat M, Shapurian R, Mehryar AH. Psychometric properties of a Persian version of the short form of the Beck Depression Inventory for Iranian college students. Psychol Rep. 1986; 59(1): 331-8[DOI][PubMed]
  • 29. Hojat M, Shapurian R, Mehryar AH. Dimensionality of the short form of the Beck Depression Inventory: a study with Iranian college students. Psychol Rep. 1986; 59(3): 1069-70[DOI][PubMed]
  • 30. Dadsetan P, Mansour M. Mental disorders. 1989;
  • 31. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005; 14(3): 875-82[PubMed]
  • 32. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005; 100(9): 1320-9[DOI][PubMed]
  • 33. McKetin R, Lubman DI, Lee NM, Ross JE, Slade TN. Major depression among methamphetamine users entering drug treatment programs. Med J Aust. 2011; 195(3)-5[PubMed]
  • 34. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R, et al. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009; 197(4): 225-31[DOI][PubMed]
  • 35. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011; 37(2): 131-6[DOI][PubMed]
  • 36. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004; 13(3): 248-55[DOI][PubMed]
  • 37. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004; 61(1): 73-84[DOI][PubMed]
  • 38. Berman SM, Voytek B, Mandelkern MA, Hassid BD, Isaacson A, Monterosso J, et al. Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol Psychiatry. 2008; 13(9): 897-908[DOI][PubMed]
  • 39. Shoptaw S, Huber A, Peck J, Yang X, Liu J, Jeff D, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006; 85(1): 12-8[DOI][PubMed]
  • 40. Zorick T, Sugar CA, Hellemann G, Shoptaw S, London ED. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug Alcohol Depend. 2011; 118(2-3): 500-3[DOI][PubMed]
  • 41. Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord. 2012; 143(1-3): 257-60[DOI][PubMed]
  • 42. Nejtek VA, Avila M, Chen LA, Zielinski T, Djokovic M, Podawiltz A, et al. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry. 2008; 69(8): 1257-66[PubMed]
  • 43. Hanley MJ, Kenna GA. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health Syst Pharm. 2008; 65(7): 611-8[DOI][PubMed]
  • 44. Ersche KD, Roiser JP, Abbott S, Craig KJ, Muller U, Suckling J, et al. Response perseveration in stimulant dependence is associated with striatal dysfunction and can be ameliorated by a D(2/3) receptor agonist. Biol Psychiatry. 2011; 70(8): 754-62[DOI][PubMed]
  • 45. Gonzales R, Ang A, Glik DC, Rawson RA, Lee S, Iguchi MY, et al. Quality of life among treatment seeking methamphetamine-dependent individuals. Am J Addict. 2011; 20(4): 366-72[DOI][PubMed]
  • 46. Gonzales R, Ang A, Marinelli-Casey P, Glik DC, Iguchi MY, Rawson RA, et al. Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period. J Subst Abuse Treat. 2009; 37(4): 353-61[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments